A STUDY OF CLINICAL, SUBCLINICAL FEATURES AND THERAPEUTIC EFFICACY OF SECUKINUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS

Abstract

Objectives: To study clinical, subclinical features and to evaluate therapeutic efficacy of Secukinumab in patients with active Ankylosing Spondylitis (AS). Patients and methods: Descriptive, comparative, retrospective and prospective study, combination with treatment intervention in patients diagnosis with AS, following to modified ACR-1984 criteria (New York criteria) who are inpatient or outpatient in the Department of General Internal Medicine - Endocrinology of Hue University of Medicine and Pharmacy and in the Department of Nephrology and Rheumatology of Hue Central Hospital from May 2018 to August 2019. Results: The study recruited of 38 patients, (76.3% males) with mean age of 29.76 ± 9.75 years old. The age of onset was about 23 years old and the percentage of patients who were diagnosed AS under 30 years old was 73.7%. The majority of patients were hospitalized with severe pain (92.1%), in which 86.8% of patients sufferred from spinal pain, 71.1% of patients showed peripheral joint pain, commonly seen in hip joints (44.7%). Other common symptoms were lumbar Schober (about 3 cm), hand to ground distance (about 20 cm), median BASDAI score: 4.15 ± 1.01, median ASDAS-CRP: 3.81 ± 0.94, increasing CRP (81.58%), increasing erythrocyte sedimentation rate (81.6%), the percentage of HLA-B27 (+): 81.25% (for patients who have received this test). For patients treated with Fraizeron, in general, there were changes in patient global assessment, noctural back pain, peripheral swelling, lumbar Schober, hand to ground distance, BASDAI, ASDAS-CRP, erythrocyte sedimentation rate, CRP. These changes were positive with p < 0.05. When we assessed the safety of Secukinumab, we did not record any clinical or subclinical undesirable effects. Conclusion: At week 16, Secukinumab has been effectively shown to improve clinical symptoms as well as subclinical symptoms in patients with AS. It is also considered safe for use in these patients. Key words: Ankylosing Spondylitis, Secukinumab